TFRC and cancer: Moreover, these aptamer-modified MSNs exhibited significantly enhanced drug delivery capabilities compared to both unmodified and randomly modified MSNs at equivalent doses and incubation times, suggesting their promise for targeted delivery to TfR-positive cancer cells and improved therapeutic efficacy [175].